Physician profile
Chirag Modi
NPI 1649701087
$2,985.24
in general payments reported to CMS, 2019-2025
13 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $101 · 2024: $2,456 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357 · Consulting Fee: $1,050 · Travel and Lodging: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.38 |
| Consulting Fee | $1,050.00 |
| Travel and Lodging | $577.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,269.10 | 2024-2025 | Barrigel |
| Astrazeneca Pharmaceuticals LP | $1,218.68 | 2023-2025 | Imfinzi, Tagrisso, Enhertu |
| Novocure INC. | $175.18 | 2025 | Optune Lua (Novottf-200t) |
| Novartis Pharmaceuticals Corporation | $71.59 | 2023-2025 | |
| Lilly USA, LLC | $50.26 | 2023-2024 | Verzenio |
| Regeneron Healthcare Solutions, INC. | $36.59 | 2024 | Libtayo |
| Janssen Biotech, INC. | $35.15 | 2024-2025 | Erleada, Tecvayli, Darzalex |
| Genentech USA, INC. | $28.55 | 2024 | Perjeta, Kadcyla, Phesgo |
| Pfizer INC. | $25.61 | 2024 | |
| Myriad Genetic Laboratories, INC. | $24.59 | 2023 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $20.06 | 2024 | |
| Seagen INC. | $15.23 | 2023 | Tukysa |
| Merck Sharp & Dohme LLC | $14.65 | 2025 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chirag Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.